| ras oncogene product p21 expression and prognosis of human ovarian tumors. | ovarian, |
| [Association of mutations of K-RAS oncogene and deletions of 18Q with lymph node metastasis of colorectal cancer]. | colorectal, |
| Naturally occurring T-cell response against mutated p21 ras oncoprotein in pancreatic cancer. | pancreatic, |
| [Expression of ras oncogene p21 in relation to prognostic factors of human breast cancer]. | breast, |
| Transformation by the k-ras oncogene correlates with increases in phospholipase A2 activity, glycerophosphoinositol production and phosphoinositide synthesis in thyroid cells. | thyroid, |
| Immunohistochemical study of oncogene product ras p21, c-myc and growth factor EGF in breast carcinomas. | breast, |
| Quantitation of enhanced expression of ras-oncogene product (p21) in childhood renal tumours. | kidney, |
| Cooperation of oncogenic K-ras and p53 deficiency in pleomorphic rhabdomyosarcoma development in adult mice. | sarcoma, |
| Frequent activation of the Ki-ras oncogene at codon 12 in N-methyl-N-nitrosourea-induced rat prostate adenocarcinomas and neurogenic sarcomas. | sarcoma,prostate, |
| Gastric epithelial cell proliferation and ras oncogene p21 expression in first-degree relatives of gastric cancer patients: a case-control study. | gastric, |
| Lack of associations among cancer and albumin adducts, ras p21 oncoprotein levels, and CYP1A1, CYP2D6, NAT1, and NAT2 in a nested case-control study of lung cancer within the physicians health study. | lung, |
| K-ras oncogene mutations in neoplasias of kidney transplanted patients: preliminary results with a new technique. | kidney, |
| Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics. | colorectal, |
| Ki-ras proto-oncogene mutation and p53 gene overexpression is associated with sporadic colorectal adenomas | colorectal, |
| Data indicate that normal intestinal and kidney epithelia are resistant to malignant transformation by an endogenous K-ras oncogene, but activation of K-ras(V12) after Apc loss results in increased tumorigenesis with distinct kinetics. | kidney, |
| Amplification and expression of c-Ki-ras oncogene in human ovarian cancer. | ovarian, |
| Tiazofurin down-regulates expression of c-Ki-ras oncogene in a leukemic patient. | leukemia, |
| Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene. | colorectal, |
| Presence of an oncogenic KRAS allele results in a dynamic physical interaction between endogenous N-RAS and gelsolin that correlates with survival in colorectal cancer cell lines. | colorectal, |
| Activation of extracellular regulated kinases (ERK1/2) but not AKT predicts poor prognosis in colorectal carcinoma and is associated with k-ras mutations. | colorectal, |